GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dermira Inc (NAS:DERM) » Definitions » Altman Z2-Score

Dermira (Dermira) Altman Z2-Score : -4.30 (As of Apr. 30, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Dermira Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Dermira has a Altman Z2-Score of -4.30, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Dermira's Altman Z2-Score or its related term are showing as below:


Dermira Altman Z2-Score Historical Data

The historical data trend for Dermira's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dermira Altman Z2-Score Chart

Dermira Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Altman Z2-Score
Get a 7-Day Free Trial - - - - -

Dermira Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Dermira's Altman Z2-Score

For the Biotechnology subindustry, Dermira's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dermira's Altman Z2-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dermira's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Dermira's Altman Z2-Score falls into.



Dermira Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Dermira's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.8112+3.26*-2.0297+6.72*-0.4523+1.05*0.0343
=-4.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Sep. 2019:
Total Assets was $436.24 Mil.
Total Current Assets was $412.52 Mil.
Total Current Liabilities was $58.64 Mil.
Retained Earnings was $-885.45 Mil.
Pre-Tax Income was -57.621 + -17.962 + -64.832 + -71.81 = $-212.23 Mil.
Interest Expense was -4.398 + -3.63 + -3.661 + -3.231 = $-14.92 Mil.
Total Liabilities was $421.76 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(412.519 - 58.638)/436.241
=0.8112

X2=Retained Earnings/Total Assets
=-885.453/436.241
=-2.0297

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-212.225 - -14.92)/436.241
=-0.4523

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(14.48 - 0)/421.761
=0.0343

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Dermira has a Altman Z2-Score of -4.30 indicating it is in Distress Zones.


Dermira  (NAS:DERM) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Dermira Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Dermira's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Dermira (Dermira) Business Description

Traded in Other Exchanges
N/A
Address
275 Middlefield Road, Suite 150, Menlo Park, CA, USA, 94025
Dermira Inc is a biopharmaceutical company focuses on the development and commercialization of medical dermatology products to dermatologists and their patients primarily in the United States.The company's late-stage product candidates include Cimzia, an injectable biologic tumor necrosis factor-alpha inhibitor to treat various inflammatory diseases, as well as to treat patients with moderate-to-severe chronic plaque psoriasis; Glycopyrronium tosylate, a small-molecule anticholinergic product that is in Phase III clinical trial for the treatment of primary axillary hyperhidrosis or excessive underarm sweating; and Olumacostat glasaretil, a small-molecule sebum inhibitor, which is in Phase III clinical trial to treat acne vulgaris or acne.
Executives
Halley E Gilbert director C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
William R Ringo director
Fred B Craves director 750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111
David E Cohen director 3160 PORTER DRIVE, PALO ALTO CA 94304
Thomas G Wiggans director, officer: CEO & Chairman of the Board
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Andrew Guggenhime officer: CFO C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Lori Lyons-williams officer: Chief Commercial Officer C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Kathleen Sebelius director C/O DERMIRA, INC., 275 MIDDLEFIELD ROAD, SUITE 150, MENLO PARK CA 94025
Eugene A Bauer director, officer: Chief Medical Officer C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Lilly Eli & Co 10 percent owner LILLY CORPORATE CENTER, DROP CODE 1094, INDIANAPOLIS IN 46285
Mark Mcdade director C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Matthew K Fust director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Canaan Partners Viii Llc director 285 RIVERSIDE AVE, STE 250, WESTPORT CT 06880
Canaan Viii Lp director 2765 SAND HILL RD, MENLO PARK CA 94025

Dermira (Dermira) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Journey Medical Corp Shares

By GuruFocus Research GuruFocus Editor 05-19-2023

This Insider Just Sold Shares of Journey Medical Corp

By GuruFocus Research GuruFocus Editor 05-20-2023